文献速递神经免疫

NMOSD与MOGAD的免疫治疗降阶梯与停药策略

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.
PubMed 文献 · Neurology · 2026-08-26

综述探讨AQP4抗体阳性NMOSD与MOGAD的免疫治疗降阶梯及停药问题。AQP4-Ab NMOSD减停后复发风险高,不建议停药;MOGAD尤其儿童可单相病程,缓解2至5年且抗体转阴后可考虑停药。妊娠等特殊情况需权衡母婴安全。

要点

  • AQP4-Ab NMOSD减量或停药后复发风险高,不应停药,降阶梯需个体化并密切监测。
  • MOGAD缓解2至5年、尤其MOG-IgG转阴者,可考虑降阶梯甚至停药。
  • 血清阴性NMOSD证据有限,停药仅基于专家意见,需谨慎。

核心结论

  • AQP4-Ab NMOSD减停后复发风险高,不建议停药;MOGAD部分患者缓解2至5年后可考虑停药。

研究设计与样本

  • 本文为综述,汇总AQP4-Ab NMOSD与MOGAD免疫治疗降阶梯及停药的观察性研究与队列证据。

主要发现

  • AQP4-Ab NMOSD多数观察性研究显示减量或停药后激活风险高,复发常严重致残。
  • MOGAD临床异质,许多患者尤其儿童为单相病程且恢复良好,成人复发风险数年后似下降。
  • MOGAD队列研究提示儿童和成人缓解2至5年后停药可行,尤其MOG-IgG转阴者。

关键数值与推荐

  • AQP4-Ab NMOSD:停药从不推荐;部分长期缓解患者可降阶梯,但复发风险持续。
  • MOGAD:抗CD20与IVIG可降阶梯;缓解2至5年、尤其MOG-IgG转阴者可考虑停药。
  • 血清阴性NMOSD:部分专家建议稳定5年后可考虑停药,仅为专家意见。

临床怎么用

  • AQP4-Ab NMOSD不应停药,降阶梯须个体化并密切监测。
  • MOGAD可依据病程、缓解时长及MOG-IgG状态考虑降阶梯或停药。
  • 妊娠期需平衡母体疾病控制与胎儿安全,可选继续、暂减或推迟治疗。
  • MRI、OCT及新兴液体生物标志物可辅助监测疾病活动,但尚未常规验证。

局限性

  • 缺乏前瞻性研究、真实世界登记数据及专门试验来指导安全降阶梯/停药策略。
  • 血清阴性NMOSD证据基础有限,预后不确定,停药建议仅基于专家意见。
  • MRI、OCT及液体生物标志物尚未验证用于常规监测疾病活动复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody-mediated inflammatory diseases of the CNS, including aquaporin-4 antibody neuromyelitis optica spectrum disorder (AQP4-Ab NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), have undergone major therapeutic transformation with the advent of sensitive antibody assays and targeted immunotherapies. These advances have markedly reduced relapse rates and improved long-term outcomes. With improved disease control, questions regarding optimal treatment duration and the possibility of de-escalation or discontinuation are increasingly relevant. In AQP4-Ab NMOSD, relapses are typically severe and disabling, and most observational studies show a high risk of reactivation after tapering or withdrawal. Thus, discontinuation is never recommended. Successful de-escalation has been reported in selected patients with prolonged remission, although relapse risk persists, underscoring the need for individualized decisions and close monitoring. In contrast, MOGAD is clinically heterogeneous. Many patients, particularly children, experience a monophasic illness with good recovery, whereas relapse risk in adults appears to decline after several years. De-escalation strategies can thus be applied for anti-CD20 and IVIG. Recent cohort studies suggest that even discontinuation may be feasible after 2 to 5 years of remission in children and adults, especially in those who become seronegative for myelin oligodendrocyte glycoprotein immunoglobulin G. In seronegative NMOSD, the evidence base is limited and prognosis uncertain; attacks can be severe, no therapies are specifically approved, and although some experts suggest that discontinuation may be considered after 5 years of stability, this remains guided by expert opinion alone. Treatment de-escalation is sometimes necessary because of adverse effects, comorbidities, infections, treatment fatigue, or life circumstances such as pregnancy. In pregnancy, management requires balancing maternal disease control with fetal safety, with strategies ranging from continuation of selected therapies to temporary tapering or deferral. Monitoring with MRI, OCT, and emerging fluid biomarkers offers potential to detect early recurrence of disease activity, although none are validated for routine use. Prospective studies, real-world registry data, and dedicated trials are urgently needed to inform safe and patient-centered de-escalation/discontinuation strategies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hacohen Y, Androdias G, Arrambide G, et al. De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD. Neurology. 2026. PMID: 42647788. doi:10.1212/WNL.0000000000218482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。